Evogliptin
This DPP-4 inhibitor works by blocking an enzyme that breaks down the hormones that stimulate insulin release after meals, helping to improve blood sugar control in type 2 diabetes. It has a prolonged duration of action.
Moleküler Ağırlık
401,4000 g/mol
LogP
1,00
TPSA
84,70 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
2D Yapı
Cite this structure
Embed this structure
SMILES
CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F
InChI
InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
Molecular Formula
C19H26F3N3O3
HBD / HBA
2 / 7
Döndürülebilir Bağlar
7
Ağır Atomlar
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This DPP-4 inhibitor works by blocking an enzyme that breaks down the hormones that stimulate insulin release after meals, helping to improve blood sugar control in type 2 diabetes. It has a prolonged duration of action.
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Yes, Evogliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1779710. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25022354. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="evogliptin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/evogliptin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/evogliptin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/evogliptin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="evogliptin"></drugfyi-drug>